Compare Stocks: SVRA, TNGX, PBLS, and RLAY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PBLS Parabilis Medicines	$29.53 -2.5%	$36.44	$24.51 ▼ $42.49	$3.74B	N/A	1.19 million shs	572,541 shs
RLAY Relay Therapeutics	$19.39 +2.3%	$19.12	$5.47 ▼ $21.27	$4.15B	1.72	3.53 million shs	2.94 million shs
SVRA Savara	$4.78 -0.6%	$5.36	$3.34 ▼ $7.01	$988.26M	0.2	2.06 million shs	2.86 million shs
TNGX Tango Therapeutics	$23.08 -0.7%	$24.77	$6.69 ▼ $34.39	$3.92B	1.17	3.23 million shs	1.94 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PBLS Parabilis Medicines	-2.48%	-9.33%	-26.94%	-2.70%	+2,952,999,900.00%
RLAY Relay Therapeutics	+2.27%	+9.61%	+1.84%	-1.77%	+253.83%
SVRA Savara	-0.62%	-5.72%	-10.99%	-23.03%	+36.96%
TNGX Tango Therapeutics	-0.69%	-5.02%	+2.49%	-23.37%	+197.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PBLS Parabilis Medicines	$29.53 -2.5%	$36.44	$24.51 ▼ $42.49	$3.74B	N/A	1.19 million shs	572,541 shs
RLAY Relay Therapeutics	$19.39 +2.3%	$19.12	$5.47 ▼ $21.27	$4.15B	1.72	3.53 million shs	2.94 million shs
SVRA Savara	$4.78 -0.6%	$5.36	$3.34 ▼ $7.01	$988.26M	0.2	2.06 million shs	2.86 million shs
TNGX Tango Therapeutics	$23.08 -0.7%	$24.77	$6.69 ▼ $34.39	$3.92B	1.17	3.23 million shs	1.94 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PBLS Parabilis Medicines	-2.48%	-9.33%	-26.94%	-2.70%	+2,952,999,900.00%
RLAY Relay Therapeutics	+2.27%	+9.61%	+1.84%	-1.77%	+253.83%
SVRA Savara	-0.62%	-5.72%	-10.99%	-23.03%	+36.96%
TNGX Tango Therapeutics	-0.69%	-5.02%	+2.49%	-23.37%	+197.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PBLS Parabilis Medicines	2.71	Moderate Buy	$41.67	41.10% Upside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	33.66% Upside
SVRA Savara	2.88	Moderate Buy	$10.00	109.21% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	88.31% Upside

Current Analyst Ratings Breakdown

Latest SVRA, TNGX, PBLS, and RLAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	PBLS Parabilis Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
10/2/2026	RLAY Relay Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/18/2026	PBLS Parabilis Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/4/2026	PBLS Parabilis Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/20/2026	RLAY Relay Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2026	RLAY Relay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $29.00
8/18/2026	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$66.00 ➝ $68.00
8/14/2026	RLAY Relay Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$28.00 ➝ $31.00
8/12/2026	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $35.00
8/11/2026	TNGX Tango Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	RLAY Relay Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	$15.35M	276.82	N/A	N/A	$3.27 per share	5.93
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A
TNGX Tango Therapeutics	$62.38M	62.38	N/A	N/A	$2.57 per share	8.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PBLS Parabilis Medicines	-$145.89M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)

Latest SVRA, TNGX, PBLS, and RLAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	PBLS Parabilis Medicines	-$0.16	-$2.32	-$2.16	-$2.32	N/A	$0.15 million
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PBLS Parabilis Medicines	N/A	17.91	17.91
RLAY Relay Therapeutics	N/A	18.27	18.27
SVRA Savara	0.21	10.13	10.13
TNGX Tango Therapeutics	N/A	50.82	50.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PBLS Parabilis Medicines	N/A
RLAY Relay Therapeutics	96.98%
SVRA Savara	87.93%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
PBLS Parabilis Medicines	N/A
RLAY Relay Therapeutics	5.04%
SVRA Savara	5.30%
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PBLS Parabilis Medicines	145	123.53 million	N/A	N/A
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable
SVRA Savara	70	205.46 million	194.57 million	Optionable
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable

SVRA, TNGX, PBLS, and RLAY Headlines

Recent News About These Companies

Tango Therapeutics (NASDAQ:TNGX) Insider Sells 27,000 Shares of Company Stock

1 hour ago | insidertrades.com

Tango Therapeutics (NASDAQ:TNGX) Stock: Insider Adam Crystal Sells 27,000 Shares

October 5 at 7:07 PM | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 5.4% - Here's Why

October 2, 2026 | marketbeat.com

Head-To-Head Analysis: GeoVax Labs (NASDAQ:GOVX) versus Tango Therapeutics (NASDAQ:TNGX)

September 30, 2026 | americanbankingnews.com

Comparing Tango Therapeutics (NASDAQ:TNGX) and Syndax Pharmaceuticals (NASDAQ:SNDX)

September 28, 2026 | americanbankingnews.com

Tango Therapeutics, Inc. (TNGX)

September 27, 2026 | finance.yahoo.com

Il principale responsabile contabile di Tango Therapeutics vende azioni per $198k

September 25, 2026 | it.investing.com

Tango Therapeutics (NASDAQ:TNGX) Insider Jessica Newcomb Sells 8,200 Shares of Stock

September 25, 2026 | insidertrades.com

600,834 Shares of Tango Therapeutics, Inc. $TNGX Purchased by Bank of America Corp DE

September 25, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock: Insider Jessica Newcomb Sells 8,200 Shares

September 24, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading 6% Higher - Here's Why

September 22, 2026 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Moderate Buy" from Analysts

September 22, 2026 | marketbeat.com

Squarepoint Ops LLC Sells 155,357 Shares of Tango Therapeutics, Inc. $TNGX

September 19, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 5.6% - Here's What Happened

September 18, 2026 | marketbeat.com

Tidal Investments LLC Purchases Shares of 55,384 Tango Therapeutics, Inc. $TNGX

September 18, 2026 | marketbeat.com

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

September 10, 2026 | zacks.com

Tango Therapeutics, Inc. $TNGX Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 10, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.5% - Still a Buy?

September 9, 2026 | marketbeat.com

Legal & General Group Plc Makes New $2.68 Million Investment in Tango Therapeutics, Inc. $TNGX

September 6, 2026 | marketbeat.com

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2026 | globenewswire.com

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, TNGX, PBLS, and RLAY Company Descriptions

Parabilis Medicines NASDAQ:PBLS

$29.53 -0.75 (-2.48%)

As of 10/5/2026 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

Relay Therapeutics NASDAQ:RLAY

$19.39 +0.43 (+2.27%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$19.36 -0.03 (-0.15%)

As of 05:22 AM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Savara NASDAQ:SVRA

$4.78 -0.03 (-0.62%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$4.99 +0.21 (+4.39%)

As of 05:36 AM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Tango Therapeutics NASDAQ:TNGX

$23.08 -0.16 (-0.69%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$23.13 +0.05 (+0.22%)

As of 04:09 AM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVRA, TNGX, PBLS, and RLAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVRA, TNGX, PBLS, and RLAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVRA, TNGX, PBLS, and RLAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, TNGX, PBLS, and RLAY Company Descriptions

Parabilis Medicines NASDAQ:PBLS

Relay Therapeutics NASDAQ:RLAY

Savara NASDAQ:SVRA

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVRA, TNGX, PBLS, and RLAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVRA, TNGX, PBLS, and RLAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVRA, TNGX, PBLS, and RLAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, TNGX, PBLS, and RLAY Company Descriptions

Parabilis Medicines NASDAQ:PBLS

Relay Therapeutics NASDAQ:RLAY

Savara NASDAQ:SVRA

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools